Predictive Oncology Stock EBITDA
| POAI Stock | USD 0.78 0.02 2.50% |
Predictive Oncology fundamentals help investors to digest information that contributes to Predictive Oncology's financial success or failures. It also enables traders to predict the movement of Predictive Stock. The fundamental analysis module provides a way to measure Predictive Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Predictive Oncology stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -13.2 M | -12.5 M |
Predictive | EBITDA |
Predictive Oncology Company EBITDA Analysis
Predictive Oncology's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Predictive Oncology EBITDA | (13.18 M) |
Most of Predictive Oncology's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Predictive Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Predictive EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Predictive Oncology is extremely important. It helps to project a fair market value of Predictive Stock properly, considering its historical fundamentals such as EBITDA. Since Predictive Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Predictive Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Predictive Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
Predictive Ebitda
Ebitda |
|
According to the company disclosure, Predictive Oncology reported earnings before interest,tax, depreciation and amortization of (13.18 Million). This is 101.5% lower than that of the Health Care Equipment & Supplies sector and 102.8% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.34% higher than that of the company.
Predictive EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Predictive Oncology's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Predictive Oncology could also be used in its relative valuation, which is a method of valuing Predictive Oncology by comparing valuation metrics of similar companies.Predictive Oncology is currently under evaluation in ebitda category among its peers.
Predictive Oncology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Predictive Oncology from analyzing Predictive Oncology's financial statements. These drivers represent accounts that assess Predictive Oncology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Predictive Oncology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 7.5M | 8.7M | 52.2M | 22.4M | 13.2M | 14.9M | |
| Enterprise Value | 12.9M | 13.9M | 24.9M | 519.2K | 7.3M | 12.6M |
Predictive Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Predictive Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Predictive Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Predictive Oncology's value.| Shares | Advisor Group Holdings, Inc. | 2024-06-30 | 425 | Psi Advisors, Llc | 2024-09-30 | 399 | Bank Of America Corp | 2024-06-30 | 33.0 | Pfs Partners, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Renaissance Technologies Corp | 2024-09-30 | 0.0 | Raymond James & Associates | 2024-06-30 | 0.0 | Jpmorgan Chase & Co | 2024-06-30 | 0.0 | Vanguard Group Inc | 2024-09-30 | 71.3 K | Geode Capital Management, Llc | 2024-09-30 | 51.9 K | Ubs Group Ag | 2024-06-30 | 35.6 K |
Predictive Fundamentals
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.56 | ||||
| Operating Margin | (11.44) % | ||||
| Current Valuation | 4.5 M | ||||
| Shares Outstanding | 6.67 M | ||||
| Shares Owned By Insiders | 2.16 % | ||||
| Shares Owned By Institutions | 4.01 % | ||||
| Number Of Shares Shorted | 160.52 K | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 2.96 X | ||||
| Revenue | 1.78 M | ||||
| Gross Profit | 1 M | ||||
| EBITDA | (13.18 M) | ||||
| Net Income | (13.98 M) | ||||
| Cash And Equivalents | 25.39 M | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 2.86 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | 2.04 X | ||||
| Cash Flow From Operations | (13.19 M) | ||||
| Short Ratio | 1.26 X | ||||
| Earnings Per Share | (2.96) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 34 | ||||
| Beta | 1.15 | ||||
| Market Capitalization | 5.18 M | ||||
| Total Asset | 14.42 M | ||||
| Retained Earnings | (167.76 M) | ||||
| Working Capital | 6.13 M | ||||
| Net Asset | 14.42 M |
About Predictive Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Predictive Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Predictive Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Predictive Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock:Check out Predictive Oncology Piotroski F Score and Predictive Oncology Altman Z Score analysis. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share 0.416 | Quarterly Revenue Growth (0.43) | Return On Assets (0.56) | Return On Equity (1.49) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.